Skip to main content
SP5007,792.49+0.57%DOW53,730.34-0.07%NASDAQ26,783.01+0.73%BTC$63,059.00-0.62%ETH$1,872.68-0.85%GOLD$4,422.60-1.01%OIL$81.96-1.57%
Smart Investors Daily
Sign InSign Up Free
MP

NASDAQ · MPLT

MapLight Therapeutics, Inc.

Healthcare · Biotechnology

$11.94

Up+$0.56 (+4.92%)

Updated Aug 13, 2026, 5:08 PM

SID Score

3.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
15.87M
P/E ratio
-8.1
Dividend yield
0.00%
52-week range
$9.10 – $40.43
Volume
111
Avg. volume
385.16K

Price performance

MPLT price history

1M range · 22 trading sessions · Daily adjusted prices

MPLT closed at $11.42 after 22 trading sessions, down 69.40% for the selected period.

Last close
$11.42
Period change
-69.40%
Period low
$9.91
Period high
$37.87
Daily close
View OHLC price history
MPLT OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Aug 13, 2026$11.57$11.57$11.422$11.422111
Aug 12, 2026$12.15$12.32$11.325$11.38478.52K
Aug 11, 2026$12.16$12.29$11.5872$11.98359.21K
Aug 10, 2026$11.06$12.52$10.84$12.18552.47K
Aug 7, 2026$13.28$13.61$12.09$12.17432.84K
Aug 6, 2026$12.76$13.74$12.71$13.28476.98K
Aug 5, 2026$13.32$13.39$12.76$12.92886.9K
Aug 4, 2026$12.57$13.03$12.37$12.94847.57K
Aug 3, 2026$12.85$13.14$12.08$12.55999.86K
Jul 31, 2026$14.42$14.99$13.00$13.021.15M
Jul 30, 2026$15.17$15.50$13.51$14.033.16M
Jul 29, 2026$12.63$16.07$12.56$15.023.09M
Jul 28, 2026$9.56$12.31$9.10$12.315.55M
Jul 27, 2026$12.98$14.50$9.905$9.9058.15M
Jul 24, 2026$35.46$36.97$34.38$36.56547.38K
Jul 23, 2026$34.86$36.035$34.495$35.23376.38K
Jul 22, 2026$37.70$37.70$35.28$35.31265.91K
Jul 21, 2026$37.30$38.26$36.03$37.44557.56K
Jul 20, 2026$38.11$38.925$35.97$35.99599.34K
Jul 17, 2026$36.37$38.625$35.52$37.87778.8K
Jul 16, 2026$36.77$38.005$35.935$37.22985.44K
Jul 15, 2026$37.54$37.78$35.52$37.33703.07K

Latest MPLT news

The latest Smart Investors Daily articles mentioning MPLT.

Stock researchCompany · Overview

MPLT research

Overview

Company profile and research snapshot.

Company profile

MapLight Therapeutics Inc is a biopharmaceutical company. The company is focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. The company is engaged in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The product candidates of the company include ML-007C-MA, ML-004, ML-021, ML-009, and other pipeline products.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$31.00
Implied upside
—
Analysts
9
MPLT recent ratings
DateFirmRatingTarget
Aug 10, 2026UBSNeutral—
Jul 28, 2026Canaccord GenuityBuy—
Jul 28, 2026Morgan StanleyEqual-Weight—
Jul 28, 2026HC Wainwright & Co.Buy—
Jul 24, 2026Canaccord GenuityBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Jan 9, 2026

MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026

SAN FRANCISCO and BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (MapLight) (Nasdaq: MPLT) today announced an update to the expected timing of topline results for its ongoing Phase 2 ZEPHYR and IRIS clinical studies, which are progressing ahead of schedule. The company’s Phase 2 ZEPHYR trial evaluating ML-007C-MA for the treatment of schizophrenia continues to enroll robustly, and topline results are now expected in the third quarter of 2026. The ZEPHYR study is a randomiz

Yahoo · Jan 5, 2026

MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer’s Disease Psychosis

SAN FRANCISCO and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (“MapLight”) (Nasdaq: MPLT) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ML-007C-MA, an investigational novel M1/M4 muscarinic agonist, for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). The Fast Track process is intended to facilitate the development and expedite the review of investigational therapi

globenewswire.com · Dec 4, 2025

MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress

Topline results from Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected in the second half of 2026 Topline results from Phase 2 VISTA trial of ML-007C-MA for Alzheimer's disease psychosis expected in the second half of 2027 Raised $296.5 million in gross proceeds from initial public offering and concurrent private placement completed in October 2025 Cash, cash equivalents and short-term investments sufficient to fund operations through 2027 SAN FRANCISCO and BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, today reported financial results for the third quarter of 2025 and highlighted recent progress and upcoming milestones. “2025 was a year of exceptional execution and acceleration for MapLight,” said Chris Kroeger, Chief Executive Officer of MapLight Therapeutics.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By